• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.

作者信息

Shi Y F, Zou M J, Schmidt H, Juhasz F, Stensky V, Robb D, Farid N R

机构信息

Thyroid Research Laboratory, Health Sciences Centre, St. John's, Newfoundland, Canada.

出版信息

Cancer Res. 1991 May 15;51(10):2690-3.

PMID:2021946
Abstract

Using polymerase chain reaction and sequence-specific oligonucleotide hybridization, the frequency of three ras oncogene mutations (N-ras, Ha-ras, and K-ras) in thyroid tumors (25 adenomas, 16 follicular carcinomas, and 22 papillary carcinomas) was investigated in both iodide-deficient and iodide-sufficient areas. The ras oncogene mutation rate was significantly higher in the iodide-deficient area, being 85 versus 17% in the adenomas, and 50 versus 10% in the follicular carcinomas. No mutations were found in papillary carcinomas. The most common mutation site was Ha-ras codon 61 with Gln----Arg substitution. Two ras mutations at codon 61 (Gln----Lys in N-ras and Gln----Arg in Ha-ras) were found in a microfollicular adenoma specimen from Eastern Hungary. We conclude that dietary iodine may modulate ras oncogene mutations, and that in the iodide-deficient area, ras oncogene activation may play a more important role in the initiation and/or maintenance of follicular tumors. Additional factors are, however, necessary to initiate carcinogenesis.

摘要

相似文献

1
High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Cancer Res. 1991 May 15;51(10):2690-3.
2
Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.甲状腺癌发生过程中Ha-ras癌基因(密码子12)突变:60例甲状腺良恶性肿瘤分析
Ann Biol Clin (Paris). 1995;53(10-11):549-55.
3
N-ras 61 oncogene mutations in Hürthle cell tumors.
Surgery. 1990 Dec;108(6):994-9; discussion 999-1000.
4
Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.切尔诺贝利核事故后受辐射儿童的良性和恶性甲状腺肿瘤中ras和p53基因突变的发生率。
Oncogene. 1996 Aug 15;13(4):687-93.
5
Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation.与辐射相关的和“自发的”人类甲状腺癌显示出不同模式的ras癌基因突变。
Oncogene. 1991 Mar;6(3):471-3.
6
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.在人类甲状腺肿瘤发生的各个阶段,ras癌基因激活的频率都很高。
Oncogene. 1989 Feb;4(2):159-64.
7
Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.人甲状腺肿瘤中ras癌基因蛋白产物的免疫组织化学分析。
Anticancer Res. 1988 Nov-Dec;8(6):1223-7.
8
Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors.
Oncogene. 1995 Aug 3;11(3):601-3.
9
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.RAS 突变与甲状腺癌的侵袭性肿瘤表型及不良预后相关。
J Clin Oncol. 2003 Sep 1;21(17):3226-35. doi: 10.1200/JCO.2003.10.130.
10
Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy.甲状腺肿瘤中线粒体D环的不稳定性并非恶性肿瘤的标志物。
Mitochondrion. 2005 Oct;5(5):333-40. doi: 10.1016/j.mito.2005.06.003.

引用本文的文献

1
Revisionist history uncovers a simplified molecular-based classification of differentiated thyroid cancer.修正主义历史揭示了一种基于分子的分化型甲状腺癌简化分类。
J Pathol. 2025 Oct;267(2):130-141. doi: 10.1002/path.6456. Epub 2025 Aug 5.
2
Effects of Trace Elements on Endocrine Function and Pathogenesis of Thyroid Diseases-A Literature Review.微量元素对内分泌功能及甲状腺疾病发病机制的影响——文献综述
Nutrients. 2025 Jan 22;17(3):398. doi: 10.3390/nu17030398.
3
Iodine nutritional status is not a direct factor in the prevalence of the mutation in papillary thyroid cancer.
碘营养状况不是甲状腺癌中突变流行的直接因素。
Arch Endocrinol Metab. 2023 Mar 10;67(2):172-178. doi: 10.20945/2359-3997000000530. Epub 2023 Jan 17.
4
Variations in kinase gladiators and risk of differentiated thyroid carcinoma.激酶斗士的变异与分化型甲状腺癌风险
Mol Clin Oncol. 2022 Feb;16(2):45. doi: 10.3892/mco.2021.2478. Epub 2021 Dec 23.
5
Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer.RAS突变在甲状腺良性结节和非髓样甲状腺癌中的意义
Cancers (Basel). 2021 Jul 27;13(15):3785. doi: 10.3390/cancers13153785.
6
Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.亚洲与西方国家滤泡状甲状腺癌的基因差异:一项系统评价
Gland Surg. 2020 Oct;9(5):1813-1826. doi: 10.21037/gs-20-356.
7
Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.用于改善甲状腺癌患者预后的多组学特征及转化潜力
Cancers (Basel). 2019 Dec 10;11(12):1988. doi: 10.3390/cancers11121988.
8
Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.碘充足国家和碘缺乏国家中分化型甲状腺癌的基因改变。
Cancer Med. 2016 Aug;5(8):1883-9. doi: 10.1002/cam4.781. Epub 2016 Jun 5.
9
Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.匈牙利甲状腺乳头状癌患者的基因改变
Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.
10
KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.KRAS(G12D)介导的甲状腺滤泡细胞致癌转化需要长期促甲状腺激素刺激,并受SPRY1调控。
Lab Invest. 2015 Nov;95(11):1269-77. doi: 10.1038/labinvest.2015.90. Epub 2015 Jul 6.